Bladder cancer is the most common malignant tumor of the urinary system, however there
are several shortcomings in current diagnostic and therapeutic measures. In terms of …

Opinion Statement Over the last several years, the treatment landscape of urothelial
carcinoma has witnessed an unprecedented expansion of therapeutic options including …

Because of low sensitivity and specificity of the currently available urine biomarkers of
bladder cancer (BC) detection and painful cystoscopy procedure. Our study aimed to …

Immunotherapies, such as immune-checkpoint blockade and adoptive T-cell therapy, offer
novel treatment options with good efficacy for patients with urothelial bladder cancer …

Bladder cancer (BC) is the sixth most common worldwide urologic malignancy associated
with elevated morbidity and mortality rates if not well treated. The muscle-invasive form of …

Purpose During the coronavirus disease 2019 (COVID-19) pandemic, the European
Association of Urology (EAU) recommended that courses of intravesical bacillus Calmette …

Background Bladder cancer is the ninth most common malignant tumor worldwide. As an
effective evidence-based multidisciplinary protocol, the enhanced recovery after surgery …

The standard treatment for non-muscle invasive bladder cancer (NMIBC) is transurethral
resection of bladder tumor (TURBT). However, this procedure may miss small lesions or …

The role of 5‐methylcytosine‐related long noncoding RNAs (m5C‐lncRNAs) in bladder
cancer (BLCA) remains unclear. Here, we aim to study the prognostic value, gene …

Background Bladder cancer is a common malignancy of the urinary system, and the survival
rate and recurrence rate of patients with muscular aggressive (MIBC) bladder cancer are not …